EDVANYSEBeveragesUS GAAP · USD

Splash Beverage Group, Inc. (NV)

Endovia Health Sciences, Inc. is a U.S.-based company organized around cannabinoid health sciences, including pharmaceutical assets, FDA-regulated human and veterinary therapeutics, and cannabinoid wellness products. The company also retains a legacy beverage distribution activity centered on Chispo tequila and operates through a public-company platform that can pursue acquisitions, licensing arrangements, and strategic partnerships.

Kysy yhtiöstä
Liikevaihto0,1milj. USD
−98,2 %v/v
Liikevoitto (EBIT)−14,2milj. USD
+11,6 %v/v
EBIT-marginaali−19 415,6%
−19 029,5 %-yks.v/v
Nettotulos−25,2milj. USD
−6,2 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−30−20−1001020milj. USD2020: 3,0 milj. USD2020: EBIT −17 milj. USD20202021: 11 milj. USD2021: EBIT −29 milj. USD20212022: 18 milj. USD2022: EBIT −21 milj. USD20222023: 19 milj. USD2023: EBIT −15 milj. USD20232024: 4,2 milj. USD2024: EBIT −16 milj. USD20242025: 0,07 milj. USD2025: EBIT −14 milj. USD20250,07−14
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Splash Beverage Group, Inc. (NV)

Liiketoiminta

Osuus liikevaihdosta
Cannabinoid wellness products30 %

Consumer-oriented cannabinoid products intended for wellness and related health applications.

Pharmaceutical and therapeutic assets30 %

Human and veterinary cannabinoid therapeutics subject to development and regulatory requirements.

Beverage distribution25 %

Legacy distribution of Chispo tequila through authorized U.S. and non-U.S. channels.

Strategic investments and partnerships15 %

Acquisitions, licensing arrangements, partnerships, and investments supporting the health sciences platform.

Tuotteet

Raportoitu · osuus liikevaihdosta
80,8%19,2%FY2025100 %
  • E Commerce80,8 %
  • Splash Beverage Group19,2 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

The legacy beverage business sells Chispo tequila through distributors and directly or indirectly to Senor Frog locations, including establishments in Florida, The Bahamas, and Mexico. The planned health sciences platform is aimed at cannabinoid wellness consumers, healthcare and veterinary markets, and potential commercial partners seeking pharmaceutical or cannabinoid technologies. Distributors, retailers, brokers, licensees, and strategic acquisition partners are important because the company relies on external channels to commercialize products and expand market access.

Senor Frog hospitality locations

Purchase Chispo tequila for beverage service in restaurants and entertainment venues.

Distributors, retailers, and brokers

Handle placement, sales, and distribution of beverage and potential wellness products.

Cannabinoid wellness consumers

Buy consumer wellness products for non-pharmaceutical health and lifestyle uses.

Human and veterinary healthcare markets

Potential users and commercial channels for regulated cannabinoid therapeutics.

Strategic partners and licensees

Provide technologies, products, capital, or market access for platform expansion.

Strategia

The company is repositioning its public-company platform from legacy branded beverages toward cannabinoid health sciences. Priorities include commercializing pharmaceutical assets, developing FDA-regulated human and veterinary therapeutics, and pursuing cannabinoid wellness and beverage products through acquisitions, licensing, and partnerships. This strategy is intended to use the company’s public-market access and industry relationships to enter higher-growth regulated markets, but execution depends on completing transactions and obtaining required approvals.

Establish the cannabinoid health sciences platformLyhyt aikaväli

The legacy beverage business has not generated sufficient scale to support the company.

Commercialize pharmaceutical and therapeutic assetsKeskipitkä aikaväli

Regulated therapeutics could provide a more defensible platform than branded beverages.

Expand through external transactionsLyhyt aikaväli

Acquisitions, licensing, and partnerships can accelerate market entry and product access.

Maantiede

Endovia is incorporated in Nevada and its current operating footprint is centered on the United States. The legacy Chispo tequila activity has been associated with Senor Frog locations in Florida, The Bahamas, and Mexico, although the reports do not provide country-level revenue allocations. Future geographic exposure will depend on regulatory approvals, distribution relationships, and the ability to commercialize cannabinoid products across permitted markets.

Riskit

Endovia’s strategic transition creates execution risk because the company must replace a small legacy beverage operation with products and assets that may require regulatory approval, development capital, and new commercial capabilities. Its beverage model also depends on distributors, retailers, brokers, and individual customer orders, limiting control over demand and market access. Financing needs, transaction uncertainty, competition, and third-party dependence could materially affect the company’s ability to implement its strategy.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Regulatory and commercialization risk1Financing and liquidity risk2Strategic transaction risk3Distribution and demand volatility4Competitive pressure5Third-party execution and compliance6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Regulatory and commercialization riskVaikutus: KriittinenTodennäköisyys: Korkea

    Human and veterinary therapeutics may require clinical, regulatory, and compliance milestones before commercialization.

    Kohdistuu: Cannabinoid pharmaceuticals and wellness products

  2. Financing and liquidity riskVaikutus: KriittinenTodennäköisyys: Korkea

    The company has historically required external financing while operating cash generation remained limited.

    Kohdistuu: Platform development and transaction funding

  3. Strategic transaction riskVaikutus: KorkeaTodennäköisyys: Korkea

    Acquisitions, divestitures, and partnerships may not close or may distract management from operating activities.

    Kohdistuu: Medterra-related transaction and future platform acquisitions

  4. Distribution and demand volatilityVaikutus: KorkeaTodennäköisyys: Korkea

    Distributors are not required to place minimum orders and may prioritize competing products.

    Kohdistuu: Legacy beverage distribution and future consumer products

  5. Competitive pressureVaikutus: KorkeaTodennäköisyys: Korkea

    Better-capitalized beverage and wellness companies can compete on pricing, marketing, and distribution.

    Kohdistuu: Branded beverages and cannabinoid consumer products

  6. Third-party execution and complianceVaikutus: KeskitasoTodennäköisyys: Korkea

    External service providers and business partners can create operational, legal, cybersecurity, and reputational exposure.

    KohdistuuDistributorsBrokersRetailersStrategic partners
Kysy Clarifolta: Splash Beverage Group, Inc. (NV)

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition

Returns, allowances, trade promotions, control transfer, and distributor sell-through affect the timing and amount of reported sales.

Vaikutus: Revenue and accounts receivable

Allowance for doubtful accounts

Changes in customer creditworthiness or collection conditions can require adjustments to receivables.

Vaikutus: Accounts receivable and bad-debt expense

Inventory valuation

Excess, obsolete, or slow-moving beverage inventory may need to be written down to net realizable value.

Vaikutus: Inventory, cost of sales, and earnings

Fair value measurements

Investments and transaction-related assets may depend on valuation techniques and assumptions.

Vaikutus: Assets, gains or losses, and equity

Acquisition and investment accounting

Future acquisitions or strategic investments could create valuation, impairment, and purchase-price allocation judgments.

Vaikutus: Goodwill, intangible assets, investments, and impairment expense

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

CV Sciences, Inc.

CVSI · Pharmaceutical Preparations

Innoviva, Inc.

INVA · Pharmaceutical Preparations

Lexaria Bioscience Corp.

LEXX · Pharmaceutical Preparations

Envista Holdings Corp

NVST · Dental Equipment & Supplies

Enhabit, Inc.

Services-Home Health Care Services

InMed Pharmaceuticals Inc.

INM · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Splash Beverage Group, Inc. (NV) (NYSE) – Beverages | Analyysi – Clarifo